EnteroMedics Inc. (NASDAQ:ETRM) said its revenue at the end of the latest quarter were 141,900%, up -0.06%% from a corresponding period a year earlier.
Since EnteroMedics Inc. incurred expenses of $89,406 to generate the revenue, its gross income in the quarter was $52,494. After deducting other operating expenses such salaries from the gross income, it ended up with a net income that gave it EPS of $(2.65).
EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, will host a conference call on Tuesday, May 16, 2017 at 8:30 AM Eastern Time to discuss results for the first quarter ended March 31, 2017 and to provide an update on the commercialization of vBloc® Neurometabolic Therapy.
Let?s look into the technical of the stock
The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.
The reported EPS resulted from dividing the net income with the number of outstanding shares. Investors should keep in mind that EnteroMedics Inc. finished the quarter with diluted outstanding shares of 1.67M.
For the next quarter, though, the analysts on Wall Street are expecting EPS of $ from EnteroMedics Inc..
EnteroMedics Inc. finished the most recent quarter with a cash balance of 3.31M%. It generated net cash flow of $(3.53M) from operations, yielding free cash flow of $(3.54M) for the quarter.
With that, the company concluded the quarter with total assets worth $7.04M. It also reported total debt of -%, with the debt having increased/decreased by falling from the previous quarter. EnteroMedics Inc. booked total liabilities of $4.1M in the latest quarter.
Analysts who have commented on EnteroMedics Inc. so far have an average recommendation of on its stock. What does that mean? A recommendation in the range of 1.00 -1.24 indicates that a stock is a BUY. A recommendation in the band of 1.75 -2.24 suggests a stock is a HOLD, and a recommendation in the range of 2.75 – 3.00 implies a stock is a SELL. So that tells you the perception of EnteroMedics Inc. on Wall Street.
However, outside BUY, HOLD and SELL, other available analyst recommendations are OVERWEIGHT and UNDERWEIGHT, represented by numbers in the range of 1.25 – 1.74 and 2.25 – 2.74, respectively.